Clinical Trials Logo

Clinical Trial Summary

Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05580042
Study type Interventional
Source TWi Biotechnology, Inc.
Contact Nicole Olszewski, study coordinator
Phone 203-785-5505
Email nicole.olszewski@yale.edu
Status Recruiting
Phase Phase 1
Start date October 3, 2022
Completion date October 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05650736 - Janus Kinase Inhibition in Granuloma Annulare Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT00720980 - Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy
Completed NCT05472636 - Evaluation of 41 Cases of Pediatric Granuloma Annulare
Terminated NCT00476697 - UVA1 Light for Scleroderma and Similar Conditions N/A
Completed NCT00129428 - Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Phase 1/Phase 2
Completed NCT03910543 - Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Phase 1